Literature DB >> 32520509

18F-FDG PET/CT Metabolic Behavior of COVID-19 Pneumonia: A Series of 4 Patients With RT-PCR Confirmation.

Domenico Albano, Luca Camoni1, Roberto Rinaldi1, Francesco Bertagna, Raffaele Giubbini.   

Abstract

Between March 26 and April 6, among 80 patients who underwent F-FDG PET/CT in our department (Brescia, Italy), 4 showed the presence of an interstitial pneumonia suspected for COVID-19 with reverse transcriptase polymerase chain reaction confirmation. All patients except one had bilateral ground-glass opacities and/or lung consolidations in at least 2 pulmonary lobes. Inferior lobes and basal segments were the most frequent site of disease. All lung lesions had an increased FDG uptake corresponding to the interstitial pneumonia, and in one case, mediastinal nodal involvement was registered.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32520509      PMCID: PMC7315840          DOI: 10.1097/RLU.0000000000003150

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   10.782


A 59-year-old man with a previous history of oral cavity cancer treated with surgery underwent an 18F-FDG PET/CT for restaging purpose. PET/CT was positive, showing the presence of local relapse at the right side of the tongue and several laterocervical lymph nodes (A and B). Moreover, FDG-positive plural diffuse interstitial alterations with ground-glass opacities (GGOs) appearance were registered with SUVmax of 13.8 (C and D). Concomitant mediastinal nodes with increased FDG uptake were present (E). A subsequent chest radiographs confirmed a diffuse interstitial pneumonia; reverse transcriptase polymerase chain reaction (RT-PCR) was positive, and the patient was hospitalized for specific therapy. A 47-year-old woman affected by an advanced stage anaplastic large-cell lymphoma relapsed after 2 chemotherapy regimen lines and was hospitalized for starting new chemotherapy cycle. Before starting, she did a nasopharyngeal swap with RT-PCR positive for COVID-19. 18F-FDG PET/CT confirmed the metabolic progression of disease with nodal, muscular, and skeletal hypermetabolic localizations (A). A moderate FDG uptake (SUVmax, 5.6) was showed in small GGOs, especially in the left inferior lobe (B–D). A subsequent chest CT demonstrated a progression of interstitial pneumonia with massive lung involvement (E–G). An asymptomatic 77-year-old man with non–Hodgkin lymphoma treated previously with one line of chemotherapy underwent an 18F-FDG PET/CT showing increased FDG uptake to several abdominal nodes consistent of relapse (A–C) and the presence of bilateral pleural thickening and FDG-avid GGOs with SUVmax of 10.2 (D–G). After the appearance of dyspnea and breathing difficulty, he went to the emergency unit and was hospitalized and started treatment with hydroxychloroquine. A 62-year-old man affected by follicular lymphoma underwent PET/CT scan for evaluating treatment response after 6 cycles of chemotherapy, and PET/CT showed a partial metabolic response with persistence of increased FDG uptake to an inguinal node (A–D) and the appearance of several bilateral lung consolidative and FDG-avid nodular areas, especially in the superior lobes with SUVmax of 9 (E–G). Being the pattern atypical for COVID-19, the patient started new chemotherapy regimen, but after the early onset of cough and dyspnea, RT-PCR test was done with positive finding for COVID-19. Chest radiographs and CT is the preferred examinations for screening, diagnosis, and monitoring of COVID-19 pneumonia.[1-3] In this setting, the role of 18F-FDG PET/CT is still unclear with only few cases present.[4-10] 18F-FDG PET/CT is a noninvasive tool with a significant role in evaluating several phlogistic and infectious pulmonary diseases, such as sarcoidosis and tuberculosis.[11] However, usually lesions presenting as GGOs are unlikely to have FDG uptake.[12] In agreement with previous articles,[6-8] our patients were characterized by the presence of bilateral peripheral consolidative areas and/or GGOs. All had increased FDG uptake higher than blood pool activity. COVID-19 do not seem to be associated with lymph node involvement; however, Qin et al[6] reported an increased nodal FDG uptake in 3 of 4 cases. Of course 18F-FDG PET/CT is not routinely recommended for pulmonary lung inflammatory diseases and not indicated in an emergency setting, but our findings underline that COVID-19 pneumonia are characterized by high 18F-FDG uptake in most cases despite GGOs appearance.
  12 in total

Review 1.  PET/CT in nononcological lung diseases: current applications and future perspectives.

Authors:  Selene Capitanio; Abdul Jalil Nordin; Abdul Rahim Noraini; Claudio Rossetti
Journal:  Eur Respir Rev       Date:  2016-09

2.  Can PET/CT help manage ground glass nodules?

Authors:  Francine L Jacobson; Jeffrey N Tarascio; Sam W Fox
Journal:  J Surg Oncol       Date:  2018-02-23       Impact factor: 3.454

3.  Incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region.

Authors:  Domenico Albano; Francesco Bertagna; Mattia Bertoli; Giovanni Bosio; Silvia Lucchini; Federica Motta; Maria Beatrice Panarotto; Alessia Peli; Luca Camoni; Frank M Bengel; Raffaele Giubbini
Journal:  J Nucl Med       Date:  2020-04-01       Impact factor: 10.057

4.  Essentials for Radiologists on COVID-19: An Update-Radiology Scientific Expert Panel.

Authors:  Jeffrey P Kanne; Brent P Little; Jonathan H Chung; Brett M Elicker; Loren H Ketai
Journal:  Radiology       Date:  2020-02-27       Impact factor: 11.105

5.  CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV).

Authors:  Michael Chung; Adam Bernheim; Xueyan Mei; Ning Zhang; Mingqian Huang; Xianjun Zeng; Jiufa Cui; Wenjian Xu; Yang Yang; Zahi A Fayad; Adam Jacobi; Kunwei Li; Shaolin Li; Hong Shan
Journal:  Radiology       Date:  2020-02-04       Impact factor: 11.105

6.  Radiographic severity index in COVID-19 pneumonia: relationship to age and sex in 783 Italian patients.

Authors:  Andrea Borghesi; Angelo Zigliani; Roberto Masciullo; Salvatore Golemi; Patrizia Maculotti; Davide Farina; Roberto Maroldi
Journal:  Radiol Med       Date:  2020-05-01       Impact factor: 3.469

7.  18F-Fluorodeoxyglucose Uptake in Patient With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Referred to Positron Emission Tomography/Computed Tomography for NSCLC Restaging.

Authors:  Giulia Polverari; Vincenzo Arena; Francesco Ceci; Ettore Pelosi; Annarita Ianniello; Elena Poli; Alberto Sandri; Daniele Penna
Journal:  J Thorac Oncol       Date:  2020-03-31       Impact factor: 15.609

8.  Incidental CT Findings Suspicious for COVID-19-Associated Pneumonia on Nuclear Medicine Examinations: Recognition and Management Plan.

Authors:  Mark Tulchinsky; Joseph S Fotos; Einat Slonimsky
Journal:  Clin Nucl Med       Date:  2020-07       Impact factor: 10.782

9.  The potential added value of FDG PET/CT for COVID-19 pneumonia.

Authors:  Yan Deng; Lei Lei; Yue Chen; Wei Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-21       Impact factor: 9.236

10.  18F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases.

Authors:  Chunxia Qin; Fang Liu; Tzu-Chen Yen; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-02-22       Impact factor: 9.236

View more
  6 in total

1.  Accidental diagnosis of COVID-19 pneumonia after 18F FDG PET/CT: a case series.

Authors:  Laura Olivari; Niccolò Riccardi; Paola Rodari; Dora Buonfrate; Stefania Diodato; Fabio Formenti; Andrea Angheben; Matteo Salgarello
Journal:  Clin Transl Imaging       Date:  2020-09-24

2.  Simultaneous Imaging of Lung Perfusion and Glucose Metabolism in COVID-19 Pneumonia.

Authors:  Celso Dario Ramos; Alins P Fernandes; Stephan P M Souza; Mariana Fujiwara; Natalia Tobar; Sergio S J Dertkigil; Maria Emília S Takahashi; Eduardo S L Gonçales; Plinio Trabasso; Denise E Zantut-Wittmann
Journal:  Am J Respir Crit Care Med       Date:  2021-05-01       Impact factor: 21.405

3.  COVID-19 pneumonia detected by [18F]FDG PET/MRI: a case with negative antigen test and chest X-ray results.

Authors:  Tetsuya Tsujikawa; Masaki Anzai; Yukihiro Umeda; Hideaki Tsuyoshi; Nobuyuki Kosaka; Hirohiko Kimura; Hidehiko Okazawa
Journal:  BJR Case Rep       Date:  2022-03-09

4.  SARS-CoV-2 infections in cancer outpatients-Most infected patients are asymptomatic carriers without impact on chemotherapy.

Authors:  Louisa Hempel; Armin Piehler; Michael W Pfaffl; Jakob Molnar; Benedikt Kirchner; Sebastian Robert; Julia Veloso; Beate Gandorfer; Zeljka Trepotec; Stefanie Mederle; Sabine Keim; Valeria Milani; Florian Ebner; Katrin Schweneker; Bastian Fleischmann; Axel Kleespies; Josef Scheiber; Dirk Hempel; Dietmar Zehn
Journal:  Cancer Med       Date:  2020-10-06       Impact factor: 4.452

5.  Incidental Findings Suggestive of COVID-19 Pneumonia in Oncologic Patients Undergoing 18F-FDG PET/CT Studies: Association Between Metabolic and Structural Lung Changes.

Authors:  Cristina Gamila Wakfie-Corieh; Federico Ferrando-Castagnetto; Alba María Blanes García; Marta García García-Esquinas; Aída Ortega Candil; Cristina Rodríguez Rey; María Nieves Cabrera-Martín; Ana Delgado Cano; José Luis Carreras Delgado
Journal:  J Nucl Med       Date:  2021-06-04       Impact factor: 10.057

Review 6.  State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation.

Authors:  Massimiliano Casali; Chiara Lauri; Corinna Altini; Francesco Bertagna; Gianluca Cassarino; Angelina Cistaro; Anna Paola Erba; Cristina Ferrari; Ciro Gabriele Mainolfi; Andrea Palucci; Napoleone Prandini; Domenico Albano; Luca Burroni; Alberto Cuocolo; Laura Evangelista; Elena Lazzeri; Natale Quartuccio; Brunella Rossi; Giuseppe Rubini; Martina Sollini; Annibale Versari; Alberto Signore; Sergio Baldari; Francesco Bartoli; Mirco Bartolomei; Adriana D'Antonio; Francesco Dondi; Patrizia Gandolfo; Alessia Giordano; Riccardo Laudicella; Michela Massollo; Alberto Nieri; Arnoldo Piccardo; Laura Vendramin; Francesco Muratore; Valentina Lavelli
Journal:  Clin Transl Imaging       Date:  2021-07-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.